Abstract
Detection of EGFR mutations in circulating tumor DNA using plasma samples is non-invasive and safety method. Cobas EGFR mutation test v2 with tumor tissue has been approved for detection of EGFR mutations to offer EGFR-TKI therapy in Japan. Recently, cobas test v2 using plasma samples at disease progression after prior EGFR-TKI therapy was approved for detection of T790M mutation. However, diagnostic accuracy of this test using plasma samples has not yet known in clinical practice.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.